MS drug Zinbryta withdrawn from European market
The relapsing multiple sclerosis treatment Zinbryta (daclizumab beta) has been by the European Medicines Agency (EMA).
The decision follows 12 reports worldwide of severe immune-mediated brain inflammation in patients taking the drug, three of which were fatal. The drug has also been linked to severe liver damage and immune-mediated disorders.
The EMA announcement means patients currently receiving Zinbryta should have their treatment stopped as soon as possible and be monitored for at least six months, and no new patients should start taking the drug.
The manufacturer Biogen had already requested the EMA withdraw the product’s marketing authorisation and notified them of their intention to cease all clinical trials of the drug. On 2 March 2018, the EMA announced it was launching an urgent review into Zinbryta and has said it will be publishing in-depth findings.
The said the drug, which received its European marketing authorisation in July 2016, is being used by fewer than 100 patients in the UK.
Citation: The Salvadore DOI: 10.1211/PJ.2018.20204516
Recommended from Pharmaceutical Press
Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.£33.00
This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.£48.00
Prescribing Medicines for Children is designed to improve understanding on all aspects of paediatric prescribing, from the development of suitable drugs through to their practical administration.£60.00
Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.£38.00
FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.£25.00